Cumberland Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Mar 11, 2022 and accepted by EDGAR at Mar 11, 2022, 17:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-10-01 to 2021-12-31 | $8.3m | us-gaap:Revenues |
| Revenue | 12 months2021-01-01 to 2021-12-31 | $35.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | $8.8m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $5.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-10-01 to 2021-12-31 | −$4.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$7.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $98.0k | us-gaap:InterestExpense |
| Income tax | 12 months2021-01-01 to 2021-12-31 | $34.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-10-01 to 2021-12-31 | −$3.8m | us-gaap:NetIncomeLoss |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$3.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-10-01 to 2021-12-31 | −$0.26 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | −$0.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-10-01 to 2021-12-31 | −$0.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | −$0.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 14,904,834 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | $6.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $103.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2021-01-01 to 2021-12-31 | $1.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-12-31 | $27.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $45.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $84.5m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $19.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $41.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $42.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-22-005942. Last ingested by Listed: Oct 26, 2026, 16:41 ET. Listed shows no prices and gives no investment advice.